ArticleCancer research2017
Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.Nature medicine · 2019Trial
- GNAQ inhibits tumorigenesis via the ARHGEF25-mediated RHOA pathway in NK/T-cell lymphoma.Cancer biology & therapy · 2025Article
- Real-World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma.Cancer medicine · 2025Article
- Advancing precision oncology with AI-powered genomic analysis.Frontiers in pharmacology · 2025Review
- Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown.Molecular oncology · 2024Article
- Bioinformatics roadmap for therapy selection in cancer genomics.Molecular oncology · 2022Review
- Clinicopathological and histological analysis of secondary malignant giant cell tumors of bone without radiotherapy.Oncology letters · 2022Article
- GNAQ T96S mutation abrogates the ability of wild-type GNAQ to induce apoptosis by phosphorylating annexin A2 in natural killer/T cell lymphoma.Cancer science · 2022Article
- Inter-assay variability of next-generation sequencing-based gene panels.BMC medical genomics · 2022Article
- Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study.PloS one · 2022Article
- Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.Genome medicine · 2021Article
- A simple method to estimate the in-house limit of detection for genetic mutations with low allele frequencies in whole-exome sequencing analysis by next-generation sequencing.BMC genomic data · 2021Article
- Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.The oncologist · 2021Article
- The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations.Journal of clinical medicine · 2020Review
- Precision oncology: the intention-to-treat analysis fallacy.European journal of cancer (Oxford, England : 1990) · 2020Article
- Article
- Impact of molecular testing in clinical practice in gynecologic cancers.Cancer medicine · 2019Article
- Interpretations of the Term "Actionable" when Discussing Genetic Test Results: What you Mean Is Not What I Heard.Journal of genetic counseling · 2019Article
- Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).Cancer biology & therapy · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Enhancements in clinical-grade next-generation sequencing (NGS) have fueled the advancement of precision medicine in the clinical oncology field. Here, we survey the molecular profiles of 1,113 patients with diverse malignancies who successfully underwent clinical-grade NGS (236-404 genes) in an academic tertiary cancer center. Among the individual tumors examined, the majority showed at least one detectable alteration (97.2%). Among 2,045 molecular aberrations was the involvement of 302 distinct genes. The most commonly altered genes were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.